Neuropharmacological Profile of an Atypical Antipsychotic, NRA0562

CNS Drug Reviews

Volumn 9, Issue 4, 2003, Pages 375-388

  Hirota, Shiho ^a,b   Kawashima, Naoya ^a   Chaki, Shigeyuki ^a   Okuyama, Shigeru ^b  

^a Medicinal Research Laboratories   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 HT2A antagonists; Atypical antipsychotics; Dopamine antagonists; NRA0562; Schizophrenia

Indexed keywords

5 [2 [4 (6 FLUORO 1H INDOL 3 YL)PIPERIDIN 1 YL]ETHYL] 4 (FLUOROPHENYL)THIAZOLE 2 CARBOXYLIC ACID AMIDE; ALPHA 1 ADRENERGIC RECEPTOR; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; METHAMPHETAMINE; NRA 0562; OLANZAPINE; RISPERIDONE; RITANSERIN; SEROTONIN 2A RECEPTOR; SERTINDOLE; UNCLASSIFIED DRUG; ZOTEPINE;

AVOIDANCE BEHAVIOR; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; HEART ARRHYTHMIA; HUMAN; IMMUNOREACTIVITY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; QT PROLONGATION; REVIEW; SCHIZOPHRENIA;

EID: 0346157993     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2003.tb00261.x     Document Type: Review

References (70)

1. Andreasen NC, Flaum M, Swayze VW, Tyrrell G, Arndt S. Positive and negative symptoms in schizophrenia: A critical reappraisal. Arch Gen Psychiatry 1990;47:615-621.
2. 1-noradrenergic antagonist. J Pharmacol Exp Ther 1997;283:666-674.
3. Baldessarini RJ, Frankenburg FR. Clozapine: A novel antipsychotic agent. N Eng J Med 1991;324:746-754.
4. Braff DL, Grillon C, Geyer M. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992;49:206-215.
5. Bunney BS. Central dopaminergic system: Two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic compounds. In: Hanin I, Usdin E, Eds. Animal Models in Psychiatry and Neurology. New York: Pergamon Press, 1997;91-104.
6. Bunney BS, Aghajanian GK. The effects of antipsychotic drugs on the firing of dopaminergic neurons: A reappraisal. In: Sedvall G, Uvnas B, Zotterman Y, Eds. Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics. New York: Pergamon Press, 1976;305-318.
7. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135:165-173.
8. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58:55-62.
9. Chaki S, Funakoshi T, Yoshikawa R, et al. In vivo receptor occupancy of NRA0045, a putative atypical antipsychotic, in rats. Neuropharmacology 1999;38:1185-1194.
10. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 1983;3:1607-1619.
11. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992;17(Suppl):5-11.
12. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
13. Creese I, Iversen SD. The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 1975;83:419-436.
14. Crow TJ, Johnstone EC, Deakin JF, Longden A. Dopamine and schizophrenia. Lancet 1976;2:563-566.
15. Cutler AJ. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;Suppl 1:69-82.
16. Dahmen N, Fehr C, Reuss S, Hiemke C. Stimulation of immediate early gene expression by desipramine in rat brain. Biol Psychiatry 1997;42:317-323.
17. Davidson AB, Weidley E. Differential effects of neuroleptic and other psychotic agents on acquisition of avoidance in rats. Life Sci 1976;18:1279-1284.
18. Deutch AY, Lee MC, Iadarole MJ. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-341.
19. 2 dopamine-receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287-297.
20. Ellinwood EH, Cohen S. Amphetamine abuse. Science 1971;171:420-421.
21. Evenden JL, Ryan CN. Behavioral responses to psychomotor stimulant drugs: Localization in the central nervous system. In: Balfour DJK, Ed. Psychotropic Drugs of Abuse. New York: Pergamon Press, 1990;1-21.
22. Fritze J, Bandelow B. The QT interval and the atypical antipsychotic, sertindole. Int J Psychiatry Clin Pract 1998;2:265-273.
23. Funakoshi T, Chaki S, Kawashima N, et al. In vitro and in vivo pharmacological profile of 5-{2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl}-4-4-fluorophenyl) thiazole-2-carboxylic acid amide (NRA0562), a novel and putative atypical antipsychotic. Life Sci 2002;71:1371-1384.
24. Gelders YG, Heylen SLE, Van den Bussche G, Reyntjens AJM, Janssen PAJ. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 1990;23:206-211.
25. Grant S, Fitton A. Risperidone: A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994;48:253-273.
26. Grohmann R, Ruther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology 1998;99:S101-S104.
27. Guo N, Klitenick MA, Tham CS, Fibiger HC. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience 1995;65:747-756.
28. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic treated patients. CNS Drugs 1998;10:209-222.
29. Hoffman DC, Donovan H. Catalepsy as a rodent model for detecting antipsychotic compounds with extrapyramidal side effect liability. Psychopharmacology 1995;120:128-133.
30. 2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685-693.
31. Kando JC, Shepski JC, Atterlee W, et al. Olanzapine: A new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 1997;31:1325-1334.
32. Kane J, Honigfield G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796.
33. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293.
34. Kawashima N, Funakoshi T, Omura T, et al. Neuropharmacological profiles of a novel atypical antipsychotic, NRA0562, in rats. Eur J Pharmacol 2001;423:27-33.
35. Kawashima N, Nakamura A, Okuyama S, Chaki S, Tomisawa K. Effects of NRA0045, NRA0160, and NRA0215 on regional Fos-like immunoreactivity in the rat brain. Gen Pharmacol 1999;32:637-646.
36. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 1996;277:968-981.
37. Kehne JH, Padich RA, McClosky TC, Taylor VL, Schmidt CJ. 5-HT modulation of auditory and visual sensorimotor gating: 1. Effects of 5-HT releasers on sound and light pre-pulse inhibition in Wistar rats. Psychopharmacology 1996;124:95-106.
38. Kelley AE, Lang CG, Gauthier AM. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. Psychopharmacology 1988;95:556-559.
39. Lee JW, Crismon ML, Dorson PG. Seizure associated with olanzapine. Ann Pharmacotherapy 1999;33:446-554.
40. MacGibbon GA, Lawlor PA, Bravo R, Dragunow M. Clozapine and haloperidol produce differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Cajella. Mol Brain Res 1994;23:21-32.
41. Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 1997;14:1-20.
42. 2 affinities differentiates atypical and typical antipsychotics drugs. Psychopharmacol Bull 1989;25:390-392.
43. Miller DD. Review and management of clozapine side effects. J Clin Psychiatry 2000;61:14-17.
44. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: Involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurosci 1991;14:421-451.
45. Ogren SO, Archer T. Effect of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile. Psychopharmacology 1994;114:383-391.
46. 2A receptor antagonist, in rats. Br J Pharmacol 1997;121:515-525.
47. 1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). J Pharmacol Exp Ther 1997;282:56-63.
48. Pijnenburg AJJ, Honig WMM, Van Rossum JM. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 1975;41:87-95.
49. Prakash A, Lamb HM. Zotepine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1998;9:153-175.
50. 2 receptor blocker. Drug Dev Res 1986;8:205-211.
51. Rigdon GC, Viik K. Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 1991;23:91-99.
52. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328.
53. Rowley M, Bristow L, Hutson P. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001;44:477-501.
54. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 1983;18:429-440.
55. 2A receptors in antipsychotic activity. Life Sci 1995;56:2209-2222.
56. Schuld A, Kuhn M, Haack M, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry 2000;33:109-111.
57. Seeman P. Brain dopamine receptors. Pharmacol Rev 1980;32:229-313.
58. 4. Neuropsychopharmacology 1992;7:261-284.
59. Sipes TA, Geyer MA. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 1994;33:441-448.
60. 2 antagonist MDL100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 1993;266:1-8.
61. 1-adrenoceptor antagonism. J Clin Psychopharmacol 1995;15:115-185.
62. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;1:139-154.
63. Swerdlow NR, Caine SB, Braff DL, Geyer MA. Neural substrates of sensorimotor gating of the startle reflex: A review of recent findings and their implications. J Psychopharmacol 1992;6:176-190.
64. Swerdlow NR, Keith VA, Braff DL, Geyer MA. Effects of spiperone, raclopride, SCH23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rats. J Pharmacol Exp Ther 1991;256:530-536.
65. Takamori K, Funakoshi T, Hirota S, Chaki S, Kameo K. Antipsychotic profile of 5-{2-[4-(6-fluoro-1H-indole-3-yl)piperidin-1-yl]ethyl}-4-(4-fluorophenyl) thiazole-2-carboxylic ic acid amide (NRA0562) in rats. Life Sci 2002;711:947-952.
66. 4 receptors. J Med Chem 1997;40:1-3.
67. Wadenberg ML, Ahlenius S, Svensson TH. Potency mismatch for behavioral and biochemical effects of dopamine receptor antagonists: Implications for the mechanism of action of clozapine. Psychopharmacology 1993;110:273-279.
68. Wagstaff AJ, Bryson HM. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995;4:370-400.
69. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic compounds on A9 and A10 dopamine neurons. Science 1983;221:1054-1057.
70. Wiesel FA, Nordstrm AL, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994;114:31-38.